During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4
- 31 August 2006
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 177 (1-2) , 161-166
- https://doi.org/10.1016/j.jneuroim.2006.04.024
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situProceedings of the National Academy of Sciences, 2003
- Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factorJournal of the Neurological Sciences, 2003
- Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 yearsJournal of the Neurological Sciences, 2002
- Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MSMultiple Sclerosis Journal, 2001
- Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®Journal of Neuroimmunology, 2001
- Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cellsBrain, 2001
- Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosisJournal of Clinical Investigation, 2000
- Immunological profile of patients with primary progressive multiple sclerosisBrain, 1999
- Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1Journal of Neuroimmunology, 1998
- Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitisProceedings of the National Academy of Sciences, 1997